Literature DB >> 1801737

The HIV-1 gag precursor is processed via two pathways: implications for cytotoxicity.

A H Kaplan1, R Swanstrom.   

Abstract

All retroviruses studied thus far contain proteases which process viral precursors to liberate the structural and enzymatic proteins of the viral capsid. We have examined the processing of the Gag precursor of HIV-1 which is composed of the viral structural proteins. Our results indicate that Gag is processed via two pathways: an expected membrane-associated pathway which gives rise to virions and a cytoplasmic pathway in which processed viral proteins accumulate in the cytoplasm. The presence of an active protease in the cytoplasm of infected cells is a potential source of toxicity. A comparison of the extent of cytoplasmic processing in lytically infected cells compared with that in cells which are not killed by the virus demonstrates a close correlation between cytoplasmic processing and cell killing.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1801737

Source DB:  PubMed          Journal:  Biomed Biochim Acta        ISSN: 0232-766X


  14 in total

1.  The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines.

Authors:  N Srinivasakumar; N Chazal; C Helga-Maria; S Prasad; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Phosphorylation and proteolytic cleavage of gag proteins in budded simian immunodeficiency virus.

Authors:  Sarah M Rue; Jason W Roos; Patrick M Tarwater; Janice E Clements; Sheila A Barber
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Authors:  Anna Stornaiuolo; Bianca Maria Piovani; Sergio Bossi; Eleonora Zucchelli; Stefano Corna; Francesca Salvatori; Fulvio Mavilio; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

4.  A packaging cell line for lentivirus vectors.

Authors:  T Kafri; H van Praag; L Ouyang; F H Gage; I M Verma
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  The HIV-1-specific protein Casp8p41 induces death of infected cells through Bax/Bak.

Authors:  Amy M Sainski; Sekar Natesampillai; Nathan W Cummins; Gary D Bren; Julie Taylor; Dyana T Saenz; Eric M Poeschla; Andrew D Badley
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

6.  Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors.

Authors:  R R Speck; C Flexner; C J Tian; X F Yu
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

7.  Engraftment of NOD/SCID mice with human CD34(+) cells transduced by concentrated oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein.

Authors:  J Gatlin; M W Melkus; A Padgett; P F Kelly; J V Garcia
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers.

Authors:  S J Arrigo; K Huffman
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Inducible human immunodeficiency virus type 1 packaging cell lines.

Authors:  H Yu; A B Rabson; M Kaul; Y Ron; J P Dougherty
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

10.  Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1.

Authors:  Martin E Adelson; Annmarie L Pacchia; Malvika Kaul; Robert F Rando; Yacov Ron; Stuart W Peltz; Joseph P Dougherty
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.